Two Data Analyses from Clinical Trials Show Epcoritamab Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma
GMAB Stock | USD 20.65 0.90 4.18% |
About 59% of Genmab AS's investor base is looking to short. The analysis of the overall investor sentiment regarding Genmab AS suggests that many traders are alarmed. The current market sentiment, together with Genmab AS's historical and current headlines, can help investors time the market. In addition, many technical investors use Genmab AS stock news signals to limit their universe of possible portfolio assets.
Genmab |
Genmab AS today announced new long-term results from two ongoing clinical trials evaluating epcoritamab, a T-cell engaging bispecific
Read at businesswire.com
Genmab AS Current Investor Sentiment
Panic Vs Confidence
41
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Genmab AS's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Genmab AS.
News SentimentNeutral | Hype SentimentBearish | Insider SentimentWaiting |
Genmab AS Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Genmab AS can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Genmab AS Historical Investor Sentiment
Investor biases related to Genmab AS's public news can be used to forecast risks associated with an investment in Genmab. The trend in average sentiment can be used to explain how an investor holding Genmab can time the market purely based on public headlines and social activities around Genmab AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Genmab AS's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Genmab AS and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Genmab AS news discussions. The higher the estimate score, the more favorable the investor's outlook on Genmab AS.
Genmab AS Fundamental Analysis
We analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Genmab AS is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Genmab AS Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Genmab AS stock to make a market-neutral strategy. Peer analysis of Genmab AS could also be used in its relative valuation, which is a method of valuing Genmab AS by comparing valuation metrics with similar companies.
Peers
Genmab AS Related Equities
PCVX | Vaxcyte | 0.69 | ||||
CYTK | Cytokinetics | 0.91 | ||||
LEGN | Legend Biotech | 0.98 | ||||
TERN | Terns Pharmaceuticals | 1.64 | ||||
BPMC | Blueprint Medicines | 2.00 | ||||
BGNE | BeiGene | 2.23 | ||||
DAWN | Day One | 2.66 | ||||
ASND | Ascendis Pharma | 2.71 | ||||
AMLX | Amylyx Pharmaceuticals | 3.10 | ||||
APLS | Apellis Pharmaceuticals | 3.71 | ||||
ALEC | Alector | 4.07 | ||||
TVTX | Travere Therapeutics | 4.12 | ||||
AKRO | Akero Therapeutics | 4.35 | ||||
EWTX | Edgewise Therapeutics | 5.54 |
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Transaction History View history of all your transactions and understand their impact on performance | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |